Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine.
Chun Yang, Mei Han, Ji-Chun Zhang, Qian Ren, Kenji Hashimoto
Psychiatry Research May 30, 2016 DOI: 10.1016/j.psychres.2016.03.034 (opens in new tab)
The journal has published a correction to this paper. Read the correction (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical animal study Peer reviewed |
|---|---|
| Population | Mouse brains |
| Interventions | Esketamine R-ketamine |
| Dose | 10mg/kg |
| Duration | Once per week for 8-weeks |
| Topics | Esketamine Ketamine |
| Keywords | Parvalbumin |
| Key points | Repeated intermittent esketamine (10 mg/kg weekly for 8 weeks), but not R-ketamine, caused loss of parvalbumin immunoreactivity in the medial prefrontal cortex and hippocampus, regions associated with psychosis. The authors suggest R-ketamine is a potent, long-lasting antidepressant free of psychotomimetic side effects and is safer than esketamine for depression treatment. |
Abstract
Clinical use of the rapid antidepressant drug ketamine is limited, due to psychotomimetic side effects. R-ketamine appears to be a potent, long-lasting and safer antidepressant, relative to S-ketamine (esketamine), since it is free of psychotomimetic side effects. Repeated, intermittent administration of esketamine (10mg/kg, once per week for 8-weeks), but not R-ketamine, caused loss of parvalbumin (PV)-immunoreactivity in the medial prefrontal cortex and hippocampus of mouse brains, regions associated with psychosis. This study suggests that repeated intermittent use of R-ketamine is safer than esketamine in the treatment of depression.
Comparable studies
Other preclinical and animal studies on esketamine, most cited first.
Citations in the library
Cited by 52
- Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms Pharmacological Reviews June 26, 2018
- Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective Psychiatry and Clinical Neurosciences June 19, 2019
- Intravenous arketamine for treatment-resistant depression: open-label pilot study European Archives of Psychiatry and Clinical Neuroscience February 20, 2020
- Mechanistic Target of Rapamycin-Independent Antidepressant Effects of (R)-Ketamine in a Social Defeat Stress Model. Biological Psychiatry 2018
- Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor Molecular Psychiatry May 7, 2021
and 47 more in the library